MariTide (Maridebart Cafraglutide): Amgen Phase 3 Status

MariTide (maridebart cafraglutide) is Amgen's investigational antibody-peptide conjugate. It activates the GLP-1 receptor and blocks the GIP receptor, so it is not a GLP-1/GIP dual agonist like tirzepatide. Amgen's August 2026 update lists it in phase 3.

How does maridebart cafraglutide work?

Amgen describes it as activating the GLP-1 receptor while antagonising the GIP receptor. The phase 2 paper describes an antibody against the GIP receptor joined to two GLP-1 analogue peptides.

What did the MariTide phase 2 trial report?

The New England Journal of Medicine trial enrolled 592 adults for 52 weeks. In adults with obesity, mean body-weight reduction was 12.3% to 16.2% against 2.5% on placebo, counting all participants. With type 2 diabetes it was 8.4% to 12.3%, against 1.7%. Gastrointestinal events were the most common adverse events.

What is the MariTide phase 3 status?

Amgen lists MARITIME-1 and MARITIME-2 as ongoing, with further phase 3 studies in cardiovascular outcomes, heart failure and sleep apnoea. It gives no readout dates and mentions no UK or EU filing.

Research use only

Peptide Labs supplies research peptides strictly for in-vitro laboratory use, not for human or animal use. This article reports public research and gives no use or dosing guidance.

Sources

• •Amgen second quarter 2026 results
• •Jastreboff et al., N Engl J Med 2025